Updated:
Beijing Jiakesi New Drugs Development Co.
Beijing Jiakesi New Drugs Development Co. is a Chinese drug development firm in Beijing, focusing on new drug R&D within China's pharmaceutical market.
Beijing Jiakesi New Drugs Development Co.
Beijing Jiakesi New Drugs Development Co. is a Chinese firm headquartered in Beijing, registered as a drug development company. Its founding year and principals are not publicly documented, and no wealth origin is disclosed. The entity operates within China's pharmaceutical sector, a landscape shaped by government initiatives like the 'Healthy China 2030' plan. The firm's strategy centers on new drug development, covering stages from preclinical research through clinical trials, with a focus on therapeutic areas common in the Chinese market. China's pharmaceutical R&D spending reached approximately $29.7 billion in 2023 (per Statista, 2024), indicating a sizable market. The company likely engages with local contract research organizations and academic partnerships. Its geographic footprint appears limited to China, without known international offices. No team size, additional offices, or affiliated vehicles are disclosed. The firm operates without publicly visible credentials or recent operational events. No verified recent activity or named portfolio companies are available from public records. A structural differentiator remains unclear due to sparse public information. In a competitive Chinese drug development sector, the firm's positioning relative to state-owned enterprises or private biotechs cannot be assessed. Succession and governance structures are unconfirmed.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Sector focus
Frequently asked questions
What is Beijing Jiakesi New Drugs Development Co.'s core business?
The firm is engaged in new drug development within China, likely covering preclinical and clinical stages. Its specific therapeutic focus is not publicly disclosed. The company operates from Beijing, China.
Does Beijing Jiakesi New Drugs Development Co. invest in early-stage or late-stage drug candidates?
Based on the firm's name and sparse public information, it likely participates in early-stage drug discovery and development. No specific pipeline or stage preferences are confirmed. The Chinese pharmaceutical market includes both early and late-stage players.
Who are the principals at Beijing Jiakesi New Drugs Development Co.?
No named principals or executive team members are identifiable from public sources. The firm does not maintain a public website or LinkedIn presence that lists leadership.
What is the known geographic focus of Beijing Jiakesi New Drugs Development Co.?
The firm is based in Beijing, China, and appears to focus exclusively on the Chinese domestic market. There is no evidence of international operations or partnerships.
Is there any publicly available information about Beijing Jiakesi New Drugs Development Co.'s funding or financials?
No financial data, including AUM, revenue, or investment amounts, is publicly disclosed. The firm's funding status remains unknown.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: